(T 11) Effect of Adding Atogepant to OnabotulinumtoxinA on Symptoms-Free Days: Results from a Phase 3, Multicenter, 24-Week Open-Label Study (UNCHAINED)

Non-presenting Author(s)

Andrew M. Blumenfeld, MD

Faculty neurologist
Cedars Sinai
Los Angeles, California, United States
JR

Jennifer Robblee, M.D., M.Sc., FRCPC

Associate Professor
Barrow Neurological Institute
Phoenix, Arizona, United States
Elizabeth K. Seng, PhD

Professor
Yeshiva University and Albert Einstein College of Medicine
Stamford, Connecticut, United States
JB

Jia Bao, PhD

AbbVie, United States
KN

Krisztian Nagy, MD, MSc

AbbVie
North Chicago, Illinois, United States
JC

Janette Contreras-De Lama, PhD

AbbVie
North Chicago, Illinois, United States
BD

Brett L. Dabruzzo, PharmD

AbbVie
Chicago, Illinois, United States

Umer Najib, MD

Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA
Morgantown, West Virginia, United States